Who is sponsoring NCT04923984?

NCT04923984 is sponsored by University of Manitoba.

What drugs are being tested in NCT04923984?

Interventions in NCT04923984: Embolization of the middle meningeal artery.

What condition does NCT04923984 study?

NCT04923984 studies Subdural Hematoma.

Is NCT04923984 still recruiting?

NCT04923984 is currently recruiting now. Last updated 3 February 2026.

Last reviewed 2026-02-03 · How we verify

NCT04923984: EMMA-Can

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Embolization of Middle Meningeal Artery for Subdural Hematoma in Canada (EMMA Can)

Recruiting now NA Last updated 3 February 2026

What this trial tests

NA trial testing Embolization of the middle meningeal artery in Subdural Hematoma in 1,000 participants. Currently enrolling.

Timeline

1 May 2021

Primary endpoint
31 December 2029

31 December 2029

Quick facts

Lead sponsor	University of Manitoba
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	1,000
Start date	1 May 2021
Primary completion	31 December 2029
Estimated completion	31 December 2029
Sites	1 location across Canada

Drugs / interventions tested

Embolization of the middle meningeal artery

Conditions studied

Subdural Hematoma — all drugs for Subdural Hematoma →

Sponsor

University of Manitoba

Who can join

18 and older, any sex, with Subdural Hematoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

EMMA-Can is a prospective cohort study to assess the safety and effectiveness of MMA-embolization for the treatment of CSDH. Hypothesis- EMMA reduces the recurrence rate of CSDH with or without concomitant surgical evacuation.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Multidisciplinary consensus-based statement on the current role of middle meningeal artery embolization (MMAE) in chronic SubDural hematoma (cSDH).
Bartek J, Biondi A, Bonhomme V, Castellan L, et al · · 2024 · cited 13× · PMID 39717364 · DOI 10.1016/j.bas.2024.104143
Newer treatment paradigm improves outcomes in the most common neurosurgical disease of the elderly: a literature review of middle meningeal artery embolization for chronic subdural hematoma.
Debs LH, Walker SE, Rahimi SY. · · 2024 · cited 13× · PMID 38691299 · DOI 10.1007/s11357-024-01173-5
A systematic review of middle meningeal artery embolization for minimally symptomatic chronic subdural haematomas that do not require immediate evacuation.
Rojas-Villabona A, Mohamed S, Kennion O, Padmanabhan R, et al · · 2023 · cited 7× · PMID 38021007 · DOI 10.1016/j.bas.2023.102672

Verify or expand the search:

Other recruiting trials for Subdural Hematoma

Currently open trials in the same condition.

NCT07143799 — Scalp Block Versus General Anesthesia in Patients Undergoing Evacuation of Subdural Hematoma Via Burr Hole · NA · recruiting

Other University of Manitoba trials

Trials by the same sponsor.

NCT07528417 — Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX) · Phase 2 · not yet recruiting
NCT07366515 — Feasibility of a Multimodal Virtual Reality Intervention to Reduce Preoperative Anxiety in Cancer Surgery Patients · NA · not yet recruiting
NCT07354386 — Effects of Dried Whole Fruits on Metabolism in Diabetes · NA · enrolling by invitation
NCT07361315 — Development and Online Evaluation of an Online Course for Parasomnias · NA · recruiting
NCT07023744 — CANnabinoids for Drug Resistant Epilepsy (DRE) in Adults and Children · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04923984 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Manitoba
Last refreshed: 3 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04923984.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing